Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Nabriva Therapeutics plc (NBRV) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/10/2022 8-K Quarterly results
08/03/2022 8-K Quarterly results
Docs: "® , the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia . Nabriva Therapeutics is also developing CONTEPO™ for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections , including acute pyelonephritis."
05/05/2022 8-K Quarterly results
11/09/2021 8-K Quarterly results
Docs: "® , the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia . Nabriva Therapeutics is also developing CONTEPO™ for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections , including acute pyelonephritis. Nabriva entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to market, sell and distribute SIVEXTRO ® in the United States and certain of its territories."
08/05/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "® , the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia . Nabriva Therapeutics is also developing CONTEPO™ for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections , including acute pyelonephritis. Nabriva entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to market, sell and distribute SIVEXTRO ® in the United States and certain of its territories."
08/06/2020 8-K Quarterly results
05/11/2020 8-K Quarterly results
03/12/2020 8-K Quarterly results
11/12/2019 8-K Quarterly results
08/08/2019 8-K Quarterly results
05/10/2019 8-K Quarterly results
Docs: "Nabriva Therapeutics Reports First Quarter 2019 Financial Results and Recent Corporate Highlights Dublin Ireland, May 10, 2019 — Nabriva Therapeutics plc , a biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, today announced its financial results for the three months ended March 31, 2019 and recent corporate highlights. “This will be a transformational year for Nabriva as we look forward to the upcoming PDUFA dates for both the intravenous and oral formulations of lefamulin for the treatment of community-acquired bacterial pneumonia ,” said Ted Schroeder, Chief Executive Officer of Nabriva Therapeutics. “Additionally, we will be working with the FDA in the coming weeks to gain a full understanding of the FDA's comments rela..."
03/12/2019 8-K Quarterly results
Docs: "Nabriva Therapeutics Reports 2018 Financial Results and Recent Corporate Highlights"
11/06/2018 8-K Quarterly results
Docs: "Nabriva Therapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights"
08/09/2018 8-K Quarterly results
Docs: "Nabriva Therapeutics Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights"
03/16/2018 8-K Quarterly results
Docs: "Nabriva Therapeutics Reports 2017 Financial Results and Recent Corporate Highlights"
11/09/2017 8-K Quarterly results
Docs: "Nabriva Therapeutics Reports Third Quarter 2017 Financial Results and Recent Corporate Highlights"
08/07/2017 8-K Quarterly results
Docs: "Nabriva Therapeutics Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights"
05/12/2017 8-K/A Quarterly results
Docs: "Nabriva Therapeutics Reports First Quarter 2017 Financial Results"
05/10/2017 8-K Quarterly results
Docs: "Nabriva Therapeutics Reports First Quarter 2017 Financial Results"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy